Clinical trials: Rosuvastatin
Obesity
Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
- Trial name
- NCT04621227
- Testing
- PF-06882961, Rosuvastatin, Midazolam
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Hypercholesterolemia, Coronary Heart Disease
Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks
The purpose of this study is to compare the effect of 8 weeks of treatment with Rosuvastatin with 8 weeks of treatment with Atorvastatin on low density lipoprotein cholesterol level in subjects with hypercholesterolemia and…
- Trial name
- POLARIS (NCT00653588)
- Testing
- Rosuvastatin, Atorvastatin
- Sponsor
- AstraZeneca
Atherosclerosis
A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis
The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.
- Trial name
- NCT02546323
- Testing
- Rosuvastatin
- Where
- 24 sites in China
- Volunteers
- 543 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, Hypercholesterolemia
Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia
To assess the efficacy and safety of rosuvastatin/ezetimibe combination therapy compared to rosuvastatin monotherapy in Korean patients with type 2 diabetes mellitus and hypercholesterolemia
- Trial name
- NCT03446261
- Testing
- Rosuvamibe® Tab, Monorova® Tab
- Where
- 2 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Yuhan Corporation
Coronary Arteriosclerosis
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries
- Trial name
- NCT00240318
- Testing
- Rosuvastatin calcium
- Where
- 61 sites in United States, Australia and 6 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Healthy
A Study of LY4065967 in Healthy Japanese Participants
The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants.
- Trial name
- NCT06594159
- Testing
- LY4065967, Rosuvastatin
- Where
- Japan
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Stroke, Ischemic, Mild Cognitive Impairment
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
Background: Dementia is an international public health problem, affecting approximately 50,000,000 people worldwide in 2018 and will triple by 2050; furthermore, reaching an approximate cost of 4 billion dollars.
- Conditions
- Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular, Metabolic Syndrome
- Trial name
- DECIST (NCT05565976)
- Testing
- Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant
- Where
- Mexico
- Volunteers
- 270 people
- Sponsor
- Jaime Daniel Mondragon
Hypertension, Hypercholesterolemia
Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol
The goal of this clinical trial is to test whether one pill that combines ezetimibe, rosuvastatin, and amlodipine can safely lower cholesterol and blood pressure in Korean adults with high blood pressure and high cholesterol.
- Trial name
- NCT07564726
- Testing
- Amlodipine, Ezetimibe/Rosuvastatin
- Where
- 21 sites in South Korea
- Volunteers
- 163 people
- Sponsor
- Celltrion Pharm, Inc.
Type 2 Diabetes Mellitus, Dyslipidemia
Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/10 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
- Trial name
- NCT04603508
- Testing
- BERLIM 25/10 association, EMPAGLIFLOZIN, ROSUVASTATIN CALCIUM
- Volunteers
- 240 people
- Sponsor
- EMS
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B.
- Trial name
- NCT06491550
- Testing
- AZD4144- Part A, AZD4144- Part B, Rosuvastatin and Furosemide- Part C
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Renal Failure
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.
- Trial name
- NCT00240331
- Testing
- 10mg Rosuvastatin
- Where
- 239 sites in Australia, Austria and 23 more
- Volunteers
- 2,776 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Atherosclerotic Plaque
Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT
INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for rosuvastatin) among statin-naive patients referred to…
- Conditions
- Coronary Artery Disease, Atherosclerotic Plaque, Coronary Computed Tomography Angiography, Statin Therapy
- Trial name
- INTENSE (NCT06603363)
- Testing
- Rosuvastatin 40mg, Coronary Computed Tomography Angiography (Coronary CTA), Blood test
- Where
- Hungary
- Volunteers
- 140 people
- Sponsor
- Prof. Maurovich-Horvat Pál
Coronary Artery Disease
The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus
This study is designed to validate the hypothesis that the treatment of rosuvastatin could increase the score of Calcification of Coronary artery(CAC) density in coronary artery disease(CAD) patients with diabetes mellitus.CAD…
- Trial name
- NCT02418884
- Testing
- rosuvastatin
- Volunteers
- 122 people
- Sponsor
- Sir Run Run Shaw Hospital
High Risk Coronary Artery Disease
A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet
This study is a randomized, open-label, 5-period, 5-treatment, single-dose, single-center, crossover study to estimate the effect of AZD5718 on the pharmacokinetics (PK) of rosuvastatin, and to assess the relative bioavailability…
- Trial name
- NCT02963116
- Testing
- AZD5718 IR tablet, AZD5718 oral suspension, Rosuvastatin tablet
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period
This project team is conducting a multicenter randomized controlled study, aiming to administer PCSK9 inhibitors subcutaneously as early as possible within 24 hours during the perioperative period of AMI (included <24h STEMI and…
- Trial name
- INCLINE-AMI (NCT07290699)
- Testing
- Recaticimab
- Volunteers
- 2,442 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Hypercholesterolemia
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Primary Objective: To evaluate the efficacy of alirocumab (75 or 150 milligrams [mg] depending on body weight [BW]), administered every 2 weeks (Q2W), on low-density lipoprotein cholesterol (LDL-C) levels at Week 12 of treatment…
- Trial name
- NCT03510715
- Testing
- Alirocumab SAR236553 (REGN727), Atorvastatin, Simvastatin
- Where
- 10 sites in Brazil, Canada and 8 more
- Volunteers
- 18 people
- Sponsor
- Sanofi
Ischemic Stroke, Atherosclerosis of Artery
Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke
The goal of this clinical trial is to evaluate whether the combination of Probucol with statin therapy can reduce the risk of vascular events and improve atherosclerosis outcomes in adults with ischemic stroke and confirmed…
- Conditions
- Ischemic Stroke, Atherosclerosis of Artery, Lipid Disorder, Statin
- Trial name
- EPCIS (NCT06604117)
- Testing
- Statin, Probucol
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xuanwu Hospital, Beijing
Abdominal Obesity
Rosuvastatin in Visceral Adiposity
The purpose of this study is to investigate whether 6 months treatment with the cholesterol-lowering drug rosuvastatin may reduce visceral fat tissue in obese middle aged men.
- Trial name
- RIVIERA (NCT01068626)
- Testing
- Rosuvastatin
- Where
- Sweden
- Volunteers
- 54 people
- Sponsor
- Göteborg University
Healthy
to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers
The purpose of this study is to compare the drug interaction of pharmacokinetics of rosuvastatin and ezetimibe.
- Trial name
- NVP-1205 (NCT02289430)
- Testing
- Crestor+Ezetrol, Ezetrol, Crestor
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- NVP Healthcare
Hypercholesterolemia
High Potency Statins and Acute Kidney Injury
Statins are a class of cholesterol lowering medications that are prescribed for the prevention and treatment of cardiovascular disease.
- Trial name
- NCT02518516
- Testing
- Rosuvastatin (≥10 mg), Atorvastatin (≥20 mg), Simvastatin (≥40 mg)
- Where
- Canada
- Volunteers
- 2,067,639 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES